RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.4 EUR | +1.98% |
|
-0.25% | -0.88% |
| May. 27 | Recordati acquires treasury shares for more than EUR3 million | AN |
| May. 21 | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... |  |
| Sales 2024 * | 2.3B 2.5B | Sales 2025 * | 2.44B 2.65B | Capitalization | 9.95B 10.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 478M 518M | Net income 2025 * | 524M 568M | EV / Sales 2024 * | 4.89 x |
| Net Debt 2024 * | 1.3B 1.41B | Net Debt 2025 * | 1.08B 1.17B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
19.4
x | Employees | 4,455 |
| Yield 2024 * |
2.91% | Yield 2025 * |
3.2% | Free-Float | 46.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
| 1 day | +1.98% | ||
| 1 week | -0.25% | ||
| Current month | -3.30% | ||
| 1 month | -3.30% | ||
| 3 months | -6.85% | ||
| 6 months | +9.58% | ||
| Current year | -0.88% |
1 week
47.28
48.86
1 month
47.2852.35
Current year
47.2853.40
1 year
41.7153.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.3057.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 18-06-11 |
Giampiero Mazza
BRD | Director/Board Member | 55 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 48.4 | +1.98% | 673,807 |
| 24-05-30 | 47.46 | -0.50% | 183,461 |
| 24-05-29 | 47.7 | -0.83% | 181,154 |
| 24-05-28 | 48.1 | -1.19% | 176,379 |
| 24-05-27 | 48.68 | +0.70% | 161,403 |
Real-time Borsa Italiana, May 31, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
48.4
EUR
Average target price
52.24
EUR
Spread / Average Target
+7.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.88% | 10.58B | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- REC Stock
